Project Grant RC3AI089207

This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...

This $405,000 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports Panorama Research Incorporated's development of a novel antibody-based immunotherapy to enhance ovarian tumor responses to treatment. The project aims to create a switchable split superantigen fused with antibodies targeting binary tumor-specific receptors, with the goal of boosting the effectiveness of immunotherapy for ovarian cancer patients. As a...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This $304,602 Project Grant was awarded on August 7, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of a novel protein engineering platform for high-throughput engineering of bispecific antibodies - therapeutic biologic molecules that are more complex and riskier to develop than traditional monoclonal antibodies. The key innovations are: 1) Displaying...

The U.S. Defense Health Agency awarded a $399,816 Project Grant to The University of British Columbia (UBC) for the project "ENGINEERING NEXT-GENERATION SELF-AMPLIFYING RNA THERAPEUTICS ENCODING BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES FOR TREATMENT OF OVARIAN CANCER." The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports UBC's research to develop innovative self-amplifying RNA-based therapies encoding bispecific T-cell engager...

This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...

The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $865,162 Project Grant to Engage Biologics Inc. to develop the Tethosome platform, a non-viral strategy for delivering and expressing therapeutic transgenes in target cells. The Tethosome system, comprised of an mRNA encoding a DNA binding protein and a non-viral DNA expression vector, aims to increase nuclear delivery of DNA and transgene expression duration without significant...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $115,000 to Navrogen Inc. to characterize HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity. The goal is to generate and test compounds that can overcome the immunosuppression mediated by HIO-2, which has been found to block antibody binding to the CD16A Fc receptor, thereby inhibiting antibody-dependent cellular cytotoxicity (ADCC)...